Symbol="CCCC"
AssetType="Common Stock"
Name="C4 TherapeuticsÂ Inc"
Description="C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts."
CIK="1662579"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="490 ARSENAL WAY, SUITE 200, WATERTOWN, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="165836000"
EBITDA="-142638000"
PERatio="None"
PEGRatio="None"
BookValue="4.763"
DividendPerShare="0"
DividendYield="0"
EPS="-2.69"
RevenuePerShareTTM="0.327"
ProfitMargin="0"
OperatingMarginTTM="-9.02"
ReturnOnAssetsTTM="-0.208"
ReturnOnEquityTTM="-0.484"
RevenueTTM="16031000"
GrossProfitTTM="-86745000"
DilutedEPSTTM="-2.69"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.807"
AnalystTargetPrice="17.64"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="8.15"
PriceToBookRatio="1.208"
EVToRevenue="3.285"
EVToEBITDA="-1.541"
Beta="2.022"
num_52WeekHigh="12.61"
num_52WeekLow="2.6"
num_50DayMovingAverage="3.421"
num_200DayMovingAverage="5.28"
SharesOutstanding="49063800"
DividendDate="None"
ExDividendDate="None"
symbol="CCCC"
open="3.38"
high="3.42"
low="3.30"
price="3.38"
volume="407814.00"
latest_trading_day="2023-08-14"
previous_close="3.41"
change="-0.03"
change_percent="-0.8798%"
aroon_positive_momentum_days="30"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="30"
Volume_recent_avg="955310"
Change_recent_avg="-0.02"
Delta_recent_avg="0.24"
Variance_recent_avg="0.12"
Change_ratio_recent_avg="-0.59"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="30"
Aroon_momentum_negative="70"
image_negative_thumbnail_id_1="119"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0057.jpeg"
image_negative_thumbnail_id_2="1108"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0141.jpeg"
image_neutral_thumbnail_id_1="538"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0061.jpeg"
image_neutral_thumbnail_id_2="574"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_positive_thumbnail_id_1="615"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0093.jpeg"
image_positive_thumbnail_id_2="684"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0024.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1198"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
